AC
RPRX icon

AlphaCore Capital’s Royalty Pharma RPRX Stock Holding History

AlphaCore Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
+5,718
New +$298K 0.01% 896

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaCore Capital's RPRX Position: Q2 2026 in Review

AlphaCore Capital opened a new position in Royalty Pharma (RPRX) in Q2 2026: 5,718 shares worth $321K. The stake represents 0.01% of the portfolio and ranks #896 among its holdings.

641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • AlphaCore Capital held 5,718 shares of Royalty Pharma worth $321K as of Q2 2026.
  • Royalty Pharma was a new AlphaCore Capital position in Q2 2026.
  • Royalty Pharma made up 0.01% of AlphaCore Capital's portfolio in Q2 2026, its #896 holding.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.